Bioengineering

Novelos Therapeutics CEO Buys 50,000 Shares of NVLT

Published in Lab Law Weekly, September 7th, 2007

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that Harry Palmin, President and CEO of Novelos, purchased 50,000 shares of the company stock on August 22, 2007, in market transactions.

"Novelos is in a pivotal Phase 3 lung cancer trial, which is on track for full enrollment in March 2008. We have Phase 2s in other cancer indications, having recently announced encouraging results in an ongoing ovarian cancer trial," said Harry Palmin, President and CEO of Novelos. "This purchase reinforces my continued confidence in Novelos and our prospects."

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2007-09-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry